The Europe Cannabidiol market size was estimated at USD 415.6 million in 2025 and is predicted to increase from USD 481.39 million in 2026 to approximately USD 1806.7 million by 2035, expanding at a CAGR of 15.83% from 2026 to 2035. The market is growing due to increasing demand for plant-based wellness products, growing medical cannabis adoption, and rising consumer interest in natural therapies for stress, pain, and sleep management. Supportive regulatory developments, innovation in CBD-infused products, and expanding retail availability across countries such as Germany, the UK, and France are further driving regional market growth.
Cannabidiol is a natural, non-psychoactive compound found in cannabis and hemp plants, commonly used in wellness, medical, and therapeutic products. The Europe cannabidiol market is growing due to increasing preference for plant-based health solutions and rising adoption og CBD in lifestyle, nutrition, and therapeutic products. Expanding product innovation in beverages, skincare, and supplements, along with improving consumer awareness about holistic wellness, is accelerating demand. In addition, supportive investments in cannabis research and wider product availability through digital and retail platforms are further strengthening market expansion across Europe.
The Europe cannabidiol market is expected to witness flexible and long-term growth driven by evolving regulations, expanding medical applications, and continuous innovation in wellness, pharmaceutical, and personal care products. Increasing consumer acceptance, rising cannabidiol research investments, and growing demand for sustainable and premium CBD solutions are likely to create strong future opportunities across the European region.
| Parameter | Data |
| Adults using cannabis annually in Europe | 24 million people |
| Annual cannabis use prevalence | 8.4% of adults (15-64 years) |
| Young adults using cannabis (15-34 years) | 15.1 million people |
| Daily or frequent cannabis users | 3.7 million adults |
| First-time cannabis treatment in Europe | 58,000 people |
| CBD Novel Food application in Europe | 194 applications |
The table highlights the growing consumer base, increasing regulatory engagements, and rising interest in cannabinoid-related products across Europe during 2024. Expanding cannabis usage, higher CBD application actively, and growing healthcare involvement indicate strong momentum for cannabidiol product innovation, medical research, and commercial expansion throughout the European region.
The hemp segment held a dominant share of 78% in 2025 due to its wider acceptance, lower THC content, and strong availability for commercial applications. Hemp-derived CBD is extensively used in wellness products, cosmetics, supplements, and pharmaceuticals because of its cost-effective cultivation and scalable production. Increasing products and supportive European regulation are further strengthening the dominance of the hemp-derived CBD segment.
The oils segment led the Europe cannabidiol market with a share of 29% in 2025 due to their high bioavailability, easy dosage control, and widespread consumer acceptance. They are widely used for stress relief, pain management, and sleep support across medical and wellness applications. Strong availability through pharmacies, online platforms, and retail stores, along with established brands’ trust and versatility in usage, further strengthened the dominance of CBD oils in the market.
The organic segment held a dominant share of 61% in 2025 and is expected to grow at the fastest CAGR in the Europe cannabidiol market during the forecast period due to rising consumer preference for clean-label, chemical-free, and sustainably sourced products. strong demand for premium wellness and skincare solutions, along with increasing health awareness, supported this dominance. Organic certification also enhances product trust, safety perception, and brand value, encouraging higher adoption across pharmacies, specialty stores, and online retail channels throughout Europe.
The medical segment held a dominant share of 41% in 2025 due to strong clinical acceptance and increasing use of CBD in testing epilepsy, chronic pain, anxiety, and neurological disorders. Growing physician prescriptions, expanding clinical research, and supportive regulatory approvals for medical cannabis products have strengthened demand. Hospitals and pharmacies play a key role in distribution, while rising patient awareness of alternative therapies further reinforces the dominance of the medical application segment.
The online retail segment led the Europe cannabidiol market with a share of 36% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to high convenience, wide product availability, and discreet purchasing options for consumers. E-commerce platforms allow easy comparison of burden, prices, and product formulations, enhancing buyer confidence. Strong digital marketing strategies, direct-to-consumer sales models, and increasing internet penetration across Europe further support growth. Fast delivery services and expanding CBD brand presence online also strengthened this channel’s dominance.
Leading companies in the Europe cannabidiol market include GW Pharmaceuticals (now part of Jazz Pharmaceuticals), Tilray, Canopy Growth Corporation, Aurora Cannabis, and Organigram Holdings Inc. These players are driving market growth through strong investments in pharmaceutical-grade cannabinoid therapies, expanding EU-focused product portfolios, and advancing clinical research in CBD-based treatments. Continuous development of medical cannabis pipelines, strategic partnerships, and growing distribution across key European markets such as Germany, the UK, and France are further strengthening their position in the region.
By Source
By Product Type
By Nature
By Application
By Distribution Channel
By End User
By Region
